logo
Robert Shapiro, Who Made NutraSweet a Household Name, Dies at 86

Robert Shapiro, Who Made NutraSweet a Household Name, Dies at 86

New York Times12-05-2025

Robert B. Shapiro, a brash former law professor turned corporate executive who performed a marketing miracle by branding aspartame as the sugar substitute NutraSweet and making it a household name that consumers demanded in thousands of products, died on May 2 at his home in Chicago. He was 86.
The cause was pancreatic cancer, his son James Shapiro said.
Aspartame was invented by chemists at the pharmaceutical company G.D. Searle in Illinois in 1965 and approved by the Food and Drug Administration for use in soft drinks in 1983, a year after Mr. Shapiro became chief executive and chairman of what the company was already calling its NutraSweet subsidiary.
Unlike its chief rival, saccharin, which had dominated the market in the 25 years since it was approved, aspartame leaves no bitter aftertaste and wasn't suspected of being linked to cancer. (In 2023, however, the World Health Organization identified aspartame, on the basis of 'limited evidence,' as 'possibly carcinogenic.') It has virtually no calories and, despite its brand name, virtually no essential nutritional value.
In 1985, Searle sold $700 million worth of aspartame, identified as NutraSweet by the tiny but distinctive red-and-white swirl logo that appeared on the packaging of food and drink products that appealed to dieters and other consumers who wanted to avoid sugar.
'Shapiro built a marketing campaign around that trademark, convincing consumers that NutraSweet (and no other company's version of the very same sweetener) was the key to losing weight,' Daniel Charles wrote in 'Lords of the Harvest: Biotech, Big Money, and the Future of Food' (2001).
Mr. Shapiro's role in branding and marketing NutraSweet, which costs more than saccharin but is sweeter, earned him a place in the 'business history books,' Jesse Meyers, the publisher of the industry newsletter Beverage Digest, told The New York Times in 1989. Products had been branded routinely, but rarely had a single ingredient that they contained.
Federal authorities approved Simplesse, a fat substitute developed by NutraSweet, as an ingredient in frozen desserts in 1988 and, later, in other products.
Searle was bought by Monsanto in 1985. Mr. Shapiro was named president of the parent company in 1993 and chief executive in 1995, as Monsanto transitioned from mostly manufacturing chemicals to making drugs and genetically modified seeds, fertilizer and food additives.
Mr. Shapiro and his colleagues insisted that biotechnology products created by the company reduced the need for pesticides and weed control, expanded the food supply and reduced the amount of land needed to farm.
When Mr. Shapiro became Monsanto's chief executive, 'he carried the company's already serious commitment to biotechnology to a whole new level, both psychologically and financially,' Rachel Schurman and William A. Munro wrote in 'Fighting for the Future of Food: Activists Versus Agribusiness in the Struggle Over Biotechnology' (2010).
'Shapiro was by all accounts a persuasive, inspiring and motivational leader,' the authors added. 'Indeed, Monsanto employees described him as a 'visionary' who swept people up with his larger sense of purpose and broad perspective on the technology.'
But environmental critics accused Monsanto of tampering with nature by concocting potentially dangerous vegetation and monopolizing the market for seeds. The company soon found itself struggling in the face of legal challenges, regulatory rulings and adverse public opinion in the United States and Europe.
'In retrospect, it seems incredibly naïve,' Mr. Shapiro said, but 'we painted a big bull's-eye on our chest.'
In a video address to the environmental advocacy group Greenpeace in 1999, Mr. Shapiro acknowledged: 'Our confidence in this technology and our enthusiasm for it has, I think, widely been seen, and understandably so, as condescension or indeed arrogance. Because we thought it was our job to persuade, too often we forgot to listen.'
William C. Miller acknowledged in his book 'Flash of Brilliance: Inspiring Creativity Where You Work' (1998) that 'some of Monsanto's products are controversial.' But, he added, 'What you can't argue about Bob Shapiro is that within his belief system, he's absolutely sincere about doing what he thinks is the way to go to address hunger and address nutrition, as the world population explodes from six billion to 10 billion.'
Robert Bernard Shapiro was born on Aug. 4, 1938, in Manhattan. His father, Moses Shapiro, was the chairman and chief executive of the electronics company General Instrument. His mother, Lilly (Langsam) Shapiro, had worked for ASCAP, the music licensing organization.
He attended the Horace Mann School in the Bronx before earning a bachelor's degree in 1959 from Harvard College, where he studied English and history, and a law degree in 1962 from Columbia Law School.
Mr. Shapiro practiced law in New York (he represented rent strikers in East Harlem and the poet Allen Ginsberg, among others, without fee) and taught at the law schools of Columbia, the University of Wisconsin and Northeastern University. He was a lawyer for the U.S. Transportation Department during the Johnson administration before joining General Instrument, where he worked from 1972 to 1979 as vice president and counsel.
He joined Searle in 1979. After Monsanto merged with Pharmacia & Upjohn in 1999, he served as chairman of the combined company, Pharmacia Corporation, until early 2001.
A liberal Democrat who had no formal training in science, Mr. Shapiro was more comfortable playing the casual college professor than the high-powered lawyer. He offered his employees free silent meditation retreats and performed as a folk guitarist. (His children Nina and James were in the alternative rock band Veruca Salt in the 1990s.)
After stepping down as chairman of Pharmacia Corporation, he was a founder of Sandbox Industries, a venture capital firm. He was also an early board member of Theranos, the blood-testing company established by Elizabeth Holmes, who was later convicted of fraud.
In addition to his son James and his daughter Nina Gordon, both from his marriage to Berta Gordon, he is survived by his wife, Ginger Farley; two children, Kai and Gabe Shapiro, from his later marriage to Kemery Bloom; his stepchildren, Harley Mac Cionaodha and Lydia Link; his sister, Susan Garfield; his brother, Bill Shapiro; and four grandchildren.
'We did proceed on the basis of our confidence in the technology,' Mr. Shapiro said of Monsanto in an interview with The Wall Street Journal in 1999. 'And we saw our products as great boons both to farmers and to the environment. I guess we naïvely thought that the rest of the world would look at the information and come to the same conclusion.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Study Shows Safety of Pharma-Grade CBD for Myocarditis
Study Shows Safety of Pharma-Grade CBD for Myocarditis

Medscape

time34 minutes ago

  • Medscape

Study Shows Safety of Pharma-Grade CBD for Myocarditis

An oral formulation of pharmaceutically manufactured cannabidiol (CBD) that targets inflammatory pathways in myocarditis and pericarditis has been shown to be as safe as placebo in not elevating cardiovascular risks, results of a prospective trial have shown. The placebo-controlled trial enrolled 89 people with a history of cardiovascular disease (CVD) and/or at least one major risk factor for the condition who had been hospitalized for noncritical COVID-19. Leslie Cooper Jr, MD 'There are 45 or so who received pharmacologically produced CBD who had no increase in overall or cardiovascular adverse events, and in particular there was no prolongation of the QT interval,' Leslie Cooper Jr, MD, chair of cardiovascular medicine at Mayo Clinic Florida in Jacksonville, Florida, told Medscape Medical News . Cooper presented a poster on the study at Heart Failure Association of the European Society of Cardiology (HFA-ESC) 2025. The findings confirmed the safety of CBD doses up to 7.5 mg/kg twice daily used in the ARCHER trial in myocarditis and the MAVERIC trial in pericarditis, Cooper said. Study Shows Safety Signal The researchers designed the study during the COVID-19 pandemic to evaluate if people hospitalized for noncritical COVID-19 with a history of or a risk factor for CVD were also at an increased risk for cardiac inflammation, Cooper said. The study was stopped early because the pandemic ended. 'The findings were underpowered for efficacy, but they did support a safety signal,' he said. The study found no significant differences in adverse events between the CBD and no-CBD groups. For example, the rate of gastrointestinal disorders was 22.2% in the CBD group and 20.5% in the placebo group. Nervous system disorders were observed in 17.8% of CBD patients vs 18.2% of placebo patients. Eleven percent of CBD patients had respiratory, thoracic, and mediastinal disorders compared with 9% of placebo patients. The rates of cardiac adverse events were also similar between the two groups. No patients in the CBD group vs three (6.8%) of those in the placebo group had tachycardia. One case of atrial fibrillation, cardiac failure, left ventricular hypertrophy, and pericardial effusion was observed in the CBD group vs none in the placebo group. One patient in the placebo group vs none in the CBD group had atrial flutter. Most cases of myocarditis are mild and resolve spontaneously without long-term consequences, Cooper said. However, about 25% of cases have significant cardiovascular sequelae, including arrhythmias and heart failure. 'We know, based on clinical grounds, how to identify those complex patients who are probably going to have a rocky long-term course,' he said. New Treatments Needed While one drug, rilonacept (Arcalyst), has been approved for the treatment of recurrent pericarditis, no approved drugs for myocarditis exist. New treatments are also needed for cardiomyopathy. Bettina Heidecker, MD, head of Heart Failure and Cardiomyopathy at the German Charité Heart Center in Berlin, Germany, told Medscape Medical News , said current therapies such as corticosteroids and other immunosuppressants carry long-term risks such as osteoporosis, metabolic disorders, infections, and organ toxicity, 'A pharmaceutically standardized CBD formulation could offer a targeted anti-inflammatory approach with a more favorable side effect profile,' Heidecker told Medscape Medical News . 'This would be particularly beneficial for younger or lower-risk patients, or those in whom prolonged immunosuppression is problematic.' Heidecker said the new data provide a rationale for continued investigation of CBD in myocarditis and pericarditis. 'It will be exciting to investigate how individual patients respond to CBD, particularly early in the treatment course,' she said. Heidecker and her team in Berlin have been studying the utility of noninvasive magnetocardiography to detect myocardial inflammation and monitor response to anti-inflammatory therapy with the hope that the approach 'may help identify early responders and guide personalized treatment strategies with CBD.' The trial was funded by Cardiol Therapeutics. Cooper is a consultant to Cardiol Therapeutics. Heidecker holds patents for RNA-based diagnostics in myocarditis and holds pending patents on magnetocardiography for diagnosing cardiomyopathy. She reported financial relationships with Biomagnetik Park Hoilding, Pfizer, and AstraZeneca.

Resistant Pneumonia Case Shakes Up Diagnostic Rules
Resistant Pneumonia Case Shakes Up Diagnostic Rules

Medscape

time40 minutes ago

  • Medscape

Resistant Pneumonia Case Shakes Up Diagnostic Rules

A 61-year-old man presented with fever, dyspnoea, cough, and maculopapular rash. The patient had no relevant medical history. Laboratory tests revealed leucocytosis. A chest x-ray showed an infiltrate in the right lower lobe of the lung, which was confirmed by CT. However, antibiotics did not improve the condition. This rare case report by Ahmad B. Al-Zughoul, MD, a resident doctor of internal medicine, Saint Agnes Medical Center, Fresno, California, describes simultaneous bacterial ( Mycoplasma pneumoniae ), viral (coronavirus NL63), and fungal ( Coccidioides spp.) pneumonia in an immunocompetent adult. The Patient and His History The patient with no past medical history presented to the emergency department with a week-long history of skin rash, fever, and shortness of breath. The patient denied any preexisting medical conditions. On admission, the patient was febrile, with a body temperature of 38.8 °C. His heart rate was tachycardic at 115 beats/min. His respiratory rate was normal. Blood pressure and oxygen saturation in room air were within their respective normal ranges. Findings and Diagnosis Physical examination showed mild pharyngeal erythema, few coarse crackles at the lung bases, and a maculopapular rash on the trunk, shoulders, and upper thighs. Laboratory findings showed leukocytes with 15.0 × 103/μL (reference range, 4.5-11.0 × 103/μL), neutrophilia of 12.22 × 103/μL (reference range, 2.6-8.2 × 103/μL), and mild eosinophilia of 0.36 × 103/μL (reference range, 0.00-0.35 × 103/μL). A multiplex polymerase chain reaction respiratory panel called BioFire, which screens for both common viral and bacterial pathogens, was performed on a nasopharyngeal swab sample, and it was positive for M pneumoniae and coronavirus. Initial immunoglobulin M (IgM) and immunoglobulin G (IgG) enzyme immunoassays for Coccidioides spp. were negative, despite the patient's residence in an endemic area. A chest x-ray revealed a right lower lung infiltrate, which was confirmed by chest as well, which did not reveal pleural effusion or lymphadenopathy. Suspecting community-acquired pneumonia, clinicians initiated 500 mg intravenous (IV) daily and ceftriaxone 1 g IV daily. After 48 hours of IV antibiotics, the patient remained symptomatic with cough and fever, and leucocytosis persisted, although the skin rash was improving. He was started on levofloxacin 750 mg IV daily to cover the possibility of macrolide-resistant M pneumoniae . The patient was still having a cough and fever 5 days into admission, with a high total white blood cell count of 17.5 × 103/μL and an increased eosinophil count of 1.08 × 103/μL. Repeat Coccidioides IgM and IgG assays then returned positive. Following the infectious disease consultation, oral fluconazole (200 mg daily) was prescribed. The patient's symptoms and blood cell counts normalised rapidly with this regimen. Discussion 'This case report sheds light on how the presence of multiple respiratory pathogens can potentially complicate the clinical course and management of pneumonia in such patients. Clinicians should be aware of the sensitivity and specificity of microbiological tests used to diagnose specific respiratory pathogens in their institution to make informed management decisions for their patients. Consultation with infectious disease specialists can be very helpful as well in complicated or difficult cases or cases not responding to appropriate management,' the study authors wrote.

Student saved by USD 428 staff after swallowing a pop lid
Student saved by USD 428 staff after swallowing a pop lid

Yahoo

timean hour ago

  • Yahoo

Student saved by USD 428 staff after swallowing a pop lid

Jun. 10—When an Eisenhower Elementary student accidentally swallowed the small metal circle from his pop can lid, three staff members saw his distress and went into action. At the June 9 USD 428 Board of Education meeting, Kelsey Strickland, Abigail Jonas and Cyleigh Unruh received the district R.O.S.E. award, Recognizing Outstanding Support of Education. School Board President Jacquie Disque read the description of what happened one month earlier. During lunchtime on Friday, May 9, a student was showing signs of distress and music teacher Kelsey Strickland immediately came to his aid. "She determined that the student accidentally swallowed the lid of a pop can, which was lodged in the student's throat." Strickland then ran to get assistance from Cyleigh Unruh, the school nurse, and Abigail Jonas, the principal. They tended to the student, kept him calm, and made sure he got immediate medical attention. "The student was taken to the emergency room and, upon evaluation, required a surgical procedure to remove the pop can lid from their esophagus. Thanks to the quick thinking and actions of these district staff, the student received prompt medical care and has made a complete recovery without any serious injuries." Board member Aaron Emerson joined Superintendent Khris Thexton in presenting the award, revealing the fact that the student in distress was his son. The metal disc from the pop can has been framed and his son no longer drinks sodas from "pop tops," Emerson said. "We're glad you were there," Disque told the staff members.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store